Position of the Transparency Council – Calcort (deflazacort)

At its meeting on 23 September 2024, the Transparency Council adopted position No. 97/2024 on the legitimacy of issuing approvals for the reimbursement of the drug Calcort (deflazacort) for the indication: severe pseudomembranous myasthenia gravis with multiple myasthenic breakthroughs

Publication of the position >>